Home » Stocks » NWBO

Northwest Biotherapeutics, Inc. (NWBO)

Stock Price: $1.25 USD -0.03 (-2.34%)
Updated November 24, 3:59 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 993.50M
Revenue (ttm) 2.06M
Net Income (ttm) -54.80M
Shares Out 794.80M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $1.25
Previous Close $1.28
Change ($) -0.03
Change (%) -2.34%
Day's Open 1.35
Day's Range 1.23 - 1.35
Day's Volume 2,301,232
52-Week Range 0.14 - 2.51

More Stats

Market Cap 993.50M
Enterprise Value 1.01B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 794.80M
Float 763.29M
EPS (basic) -0.08
EPS (diluted) -0.09
FCF / Share -0.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14.14M
Short Ratio 13.54
Short % of Float 1.85%
Beta 0.85
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 481.81
PB Ratio n/a
Revenue 2.06M
Operating Income -28.23M
Net Income -54.80M
Free Cash Flow -27.74M
Net Cash -14.89M
Net Cash / Share -0.02
Gross Margin -542.19%
Operating Margin -1,369.01%
Profit Margin -2,657.40%
FCF Margin -1,345.25%
ROA -119.17%
ROE n/a
ROIC 181.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$15.10*
Low
15.1
Current: $1.25
High
15.1
Target: 15.10
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2.410.410.340.621.741.450.810.770.010.01
Revenue Growth484.95%22.62%-46.07%-64.17%19.6%79.73%4.79%7620%0%-
Gross Profit2.410.410.340.621.741.450.810.770.010.01
Operating Income-27.46-41.48-54.68-79.27-126-101-55.47-43.83-26.79-15.35
Net Income-20.30-35.79-73.14-80.21-115-136-65.79-67.32-32.83-27.37
Shares Outstanding56444024311177.7159.2532.8711.765.894.19
Earnings Per Share-0.04-0.12-0.31-0.77-1.48-2.29-2.00-5.72-5.58-6.56
Operating Cash Flow-31.86-34.59-36.50-55.65-79.71-54.58-37.80-22.75-14.71-6.38
Capital Expenditures-0.3645.400.21-4.94-6.75-33.73--0.03-0.05-0.04
Free Cash Flow-32.2210.82-36.28-60.59-86.46-88.30-37.80-22.79-14.76-6.42
Cash & Equivalents0.3722.220.126.8722.7014.2618.507.350.020.15
Total Debt18.0316.8031.4331.7122.8123.681.223.8715.269.95
Net Cash / Debt-17.665.43-31.31-24.84-0.11-9.4217.283.47-15.23-9.80
Assets9.1324.6748.9152.9170.8056.4618.787.570.210.29
Liabilities52.7071.8396.2079.4175.4791.4819.6912.6352.3927.98
Book Value-43.57-47.16-67.33-26.50-4.68-35.03-9.82-16.07-52.17-27.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Northwest Biotherapeutics, Inc.
Country United States
Employees 17
CEO Linda F. Powers

Stock Information

Ticker Symbol NWBO
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: NWBO

Description

Northwest Biotherapeutics, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L that is in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, which is in Phase I/II clinical trials to treat various inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.